Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00664898
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 10
- Registration Number
- NCT00657553
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, United States
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-09-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00652041
- Locations
- 🇪🇸
Hospital de la Diputación de Navarra, Navarra, Spain
🇪🇸Hospital Morales Messeguer, Murcia, Spain
🇪🇸Hospital La Fe, Valencia, Spain
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00651781
- Locations
- 🇪🇸
Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Santa Creu y Sant Pau.Barcelona, Barcelona, Spain
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 525
- Registration Number
- NCT00644228
- Locations
- 🇺🇸
Good Samaritan Hospital - Dayton, Dayton, Ohio, United States
🇺🇸Miami Valley Hospital, Dayton, Ohio, United States
🇺🇸Miami Valley Hospital North, Dayton, Ohio, United States
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 61
- Registration Number
- NCT00642395
- Locations
- 🇫🇷
Service of Hematology -Henri Becquerel Center, Rouen, France
🇫🇷Service of Blood Deseases - South Hospital, Amiens, France
🇫🇷Service of Clinical Hematology - F. Baclesse Center, Caen, France
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00641706
- Locations
- 🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸Illinois CancerCare Galesburg, Galesburg, Illinois, United States
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 37
- Registration Number
- NCT00634179
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00633594
- Locations
- 🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States
🇺🇸RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2011-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00629226
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.